Fundraising Fox
/Companies
Sign in

IsoRay

NYSE: CATX

Richland, US · Delaware corporation

Find your way into IsoRay

Sign up to see every warm intro you have to IsoRay

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the IsoRay team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Perspective Therapeutics is a radiopharmaceutical company developing image-guided, targeted alpha-particle therapies for cancer, using Pb-212-based radiotherapies delivered to tumor cells via high-affinity targeting peptides. It runs a clinical-stage pipeline of theranostic programs for indications including neuroendocrine tumors, melanoma, and other solid tumors.

BiotechHealthtechMedical Devices

Founders & leadership

J(
Johan (Thijs) SpoorChief Executive Officer, Director
WC
William CavanaghNamed on SEC filing
MW
Michael W McCormickNamed on SEC filing
LA
Lori A WoodsNamed on SEC filing
JS
Jennifer StreeterNamed on SEC filing
MJ
Mark J AustinNamed on SEC filing
MK
Michael KrachonNamed on SEC filing
AH
Alan HoffmannNamed on SEC filing
PJ
Philip J VitaleNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$163.6M disclosed across 4 rounds · 2018–2024

▶$87.4MraisedMar 2024 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert Williamson IIIDirector
  • Frank MorichDirector
  • Johan (Thijs) SpoorExecutive Officer, Director
  • Lori WoodsDirector
  • Mark AustinExecutive Officer
  • Heidi HensonDirector
  • Jonathan HuntExecutive Officer
  • Markus PuhlmannExecutive Officer
Offering amount
$87.4M
Amount sold
$87.4M
Sales commissions
$5.1M
Placement agents
LifeSci Capital, LLC, Oppenheimer & Co. Inc., B. Riley Securities, Inc., JonesTrading Institutional Services LLC
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.8MraisedJan 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert Williamson IIIDirector
  • Markus PuhlmannExecutive Officer
  • Mark AustinExecutive Officer
  • Johan (Thijs) SpoorExecutive Officer, Director
  • Frank MorichDirector
  • Heidi HensonDirector
  • Jonathan HuntExecutive Officer
  • Lori WoodsDirector
Offering amount
$20.8M
Amount sold
$20.8M
Minimum investment
$20.8M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$54.6MraisedFeb 2023 · 54 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Lori WoodsDirector
  • Mark AustinExecutive Officer
  • Markus PuhlmannExecutive Officer
  • Johan (Thijs) SpoorExecutive Officer, Director
  • Frank MorichDirector
  • Robert Williamson IIIDirector
  • Michael McCormickDirector
  • Jennifer StreeterExecutive Officer
  • Jonathan HuntExecutive Officer
Offering amount
$54.6M
Amount sold
$54.6M
Minimum investment
$28.5K
First sale
Feb 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$728.8KraisedJul 2018 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • William CavanaghExecutive Officer
  • Michael W McCormickDirector
  • Lori A WoodsExecutive Officer, Director
  • Jennifer StreeterExecutive Officer
  • Mark J AustinExecutive Officer
  • Michael KrachonExecutive Officer
  • Alan HoffmannDirector
  • Philip J VitaleDirector
Offering amount
$728.8K
Amount sold
$728.8K
Sales commissions
$46.2K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2018
Incorporated
Corporation, Minnesota
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does IsoRay do?
Perspective Therapeutics is a radiopharmaceutical company developing image-guided, targeted alpha-particle therapies for cancer, using Pb-212-based radiotherapies delivered to tumor cells via high-affinity targeting peptides. It runs a clinical-stage pipeline of theranostic programs for indications including neuroendocrine tumors, melanoma, and other solid tumors.
How much funding has IsoRay raised?
IsoRay has disclosed $163.6M raised across 4 rounds.
Where is IsoRay headquartered?
IsoRay is headquartered in Richland, US.